Molecular approaches for new vaccines against allergy

References

• Wüthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss study on air pollution and lung diseases in Adults. Int. Arch. Allergy Immunol. 106, 149–56 (1995).
   PubMed Web of Science ®Google Scholar
• Valenta R, Kraft D. Recombinant allergen molecules: tools to study effector cell activation. Immunol. Rev. 179, 119–27 (2001).
   PubMed Web of Science ®Google Scholar
• Mari A, Riccioli D. The Allergome website – a database of allergenic molecules. Aim, structure, and data of a web-based resource. J. Allergy Clin. Immunol. 113, S301 (2004).
   Google Scholar
• Recombinant allergens. In: Methods 32 Valenta R, Kraft D (Eds). 3, (2004).
   Google Scholar
• Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr. Opin. Immunol. 14, 718–727 (2002).
   PubMed Web of Science ®Google Scholar
• Valenta R, Ball T, Focke M et al. Immunotherapy of allergic disease. Adv. Immunol. 82, 105–153 (2004).
   PubMed Web of Science ®Google Scholar
• Niederberger V, Niggemann B, Kraft D, Spitzauer S, Valenta R. Evolution of IgM, IgE and IgG1–4 antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms. Eur. J. Immunol. 32, 576–584 (2002).
   PubMed Web of Science ®Google Scholar
• Asthma Prevention and Management Guidelines. Makino S, Ohta K, Nishima S, Morikawa A (Eds). Int. Arch. Allergy Immunol. 136(Suppl. 1) (2005).
   Google Scholar
• Brown NJ, Robers LJ. Histamine, bradykinin, and their antagonists. In: The Pharmacological Basis of Therapeutics. Hardmann JG, Limbird LE (Eds), McGraw-Hill, 645–667 (2001).
   Google Scholar
• Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and Aactions of adrenocortical hormones. In: The Pharmacological Basis of Therapeutics. Hardmann JG, Limbird LE (Eds), McGraw-Hill 1649–1677 (2001).
   Google Scholar
• Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs. BMJ 302, 265–269 (1991).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102, 558–562 (1998).
   PubMed Web of Science ®Google Scholar
• Moller S, Dreborg HA, Ferdousi S et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109, 251–256 (2002).
   PubMed Web of Science ®Google Scholar
• Lockey RF. ‘ARIA’: global guidelines and new forms of allergen immunotherapy. J. Allergy Clin. Immunol. 108, 497–499 (2001).
   PubMed Web of Science ®Google Scholar
• Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J. Allergy Clin. Immunol. 111, 437–448 (2003).
   PubMed Web of Science ®Google Scholar
• Reider N. Sublingual immunotherapy for allergic rhinoconjunctivitis - the seeming and the real. Int. Arch. Allergy Immunol. 137, 181–186 (2005).
   PubMed Web of Science ®Google Scholar
• Golden B, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J. Allergy Clin. Immunol. 97, 579–587 (1996).
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468–475 (1999).
   PubMed Web of Science ®Google Scholar
• Noon L. Prophylactic inoculation of hay-fever. Lancet 1, 1572–1573 (1911).
   Google Scholar
• Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13, 603–609 (1999).
   PubMed Web of Science ®Google Scholar
• Flicker S, Valenta R. Renaissance of the blocking antibody concept in Type I allergy. Int. Arch. Allergy Immunol. 132, 13–24 (2003).
   PubMed Web of Science ®Google Scholar
• Gastaminza G, Algorta J, Audicana M et al. Systemic reactions to immunotherapy: influence of composition and manufacturer. Clin. Exp. Allergy 33, 470–4 (2003).
   PubMed Web of Science ®Google Scholar
• Grier TJ, Hazlhurst DM, Duncan EA, West TK, Esch RE. Major allergen measurements: sources of variability, validation, quality assurance, and utility for laboratories, manufacturers, and clinics. Allergy Asthma Proc. 23, 125–131 (2002).
   PubMed Web of Science ®Google Scholar
• van der Veen MJ, Mulder M, Witteman AM et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite. J. Allergy Clin. Immunol. 98, 1028–1034 (1996).
   PubMed Web of Science ®Google Scholar
• Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J. Allergy Clin. Immunol. 111, 777–783 (2003).
   PubMed Web of Science ®Google Scholar
• Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted IgE production and inhibition of basophil histamine release by blocking antibodies. Clin. Exp. Allergy 33, 1198–1208 (2003).
   PubMed Web of Science ®Google Scholar
• van Hage-Hamsten M, Valenta R. Specific immunotherapy - the induction of new IgE specificities? Allergy 57, 375–378 (2002).
   PubMed Web of Science ®Google Scholar
• Movérare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specifities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP system. Allergy 57, 423–430 (2002).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee of the American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J. Allergy Clin. Immunol. 113, 1129–1136 (2004).
   PubMed Web of Science ®Google Scholar
• Marsh DG. Preparation and properties of allergoids, derived from native pollen allergens by mild formalin treatment. Int. Arch. Allergy Appl. Immunol. 41, 199–215 (1971).
   PubMedGoogle Scholar
• Klimek L, Dormann D, Jarmann ER et al. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin. Exp. Allergy 29, 1326–1335 (1999).
   PubMed Web of Science ®Google Scholar
• King TP, Spangfort MD. Structure and biology of stinging insect venom allergens. Int. Arch. Allergy Immunol. 123, 99–106 (2000).
   PubMed Web of Science ®Google Scholar
• Breiteneder H, Ebner C. Molecular and biochemical classification of plant-derived food allergens. Int. Arch. Allergy Immunol. 106, 27–36 (2000).
   Google Scholar
• Rodriguez R, Villalba M, Monsalve RI, Batanero E. The spectrum of olive pollen allergens. Int. Arch. Allergy Immunol. 125, 185–195 (2001).
   PubMed Web of Science ®Google Scholar
• Thomas WR, Smith WA, Hales BJ, Mills KL, O´Brien RM. Characterization and immunobiology of house dust mite allergens. Int. Arch. Allergy Immunol. 129, 1–18 (2002).
   PubMed Web of Science ®Google Scholar
• Kurup VP, Shen HD, Vijay H. Immunobiology of fungal allergens. Int. Arch. Allergy Immunol. 129, 181–188 (2002).
   PubMed Web of Science ®Google Scholar
• Andersson K, Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int. Arch. Allergy Immunol. 130, 87–107 (2003).
   PubMed Web of Science ®Google Scholar
• Roux KH, Teuber SS, Sathe SK. Tree nut allergens. Int. Arch Allergy. Immunol. 131, 234–244 (2003).
   PubMed Web of Science ®Google Scholar
• Colombo P, Bonura A, Costa M et al. The allergens of Parietaria. Int. Arch. Allergy Immunol. 130, 173–179 (2003).
   PubMed Web of Science ®Google Scholar
• Valenta R, Vrtala S, Focke-Tejkl M et al. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against Type I allergy. Biol. Chem. 380, 815–824 (1999).
   PubMed Web of Science ®Google Scholar
• Hiller R, Laffer S, Harwanegg C et al. Microarrayed allergen-molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 16, 414–416 (2002).
   PubMed Web of Science ®Google Scholar
• Kazemi-Shirazi L, Niederberger V, Linhart B et al. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int. Arch. Allergy Immunol. 127, 259–268 (2002).
   PubMed Web of Science ®Google Scholar
• Pittner G, Vrtala S, Thomas WR et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin. Exp. Allergy 34, 597–603 (2004).
   PubMed Web of Science ®Google Scholar
• Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin. Exp. Allergy 29, 896–904 (1999).
   PubMed Web of Science ®Google Scholar
• Vrtala S, Ball T, Spitzauer S et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induces basophil degranulation. J. Immunol. 160, 6137–6144 (1998).
   PubMed Web of Science ®Google Scholar
• Swoboda I, Bugajska-Schretter A, Verdino P et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: tool for diagnosis and therapy of fish allergy. J. Immunol. 168, 4576–4584 (2002).
   PubMed Web of Science ®Google Scholar
• Orlandi A, Grasso F, Corinti S et al. The recombinant major allergen of Paritaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin. Exp. Allergy 34, 470–477 (2004).
   PubMed Web of Science ®Google Scholar
• Holt PG, Patty JE, Turner KG. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. Immunology 42, 409–417 (1981).
   PubMed Web of Science ®Google Scholar
• Tsitoura DC, DeKruyff RH, Lamb JR, Umetsu DT. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J. Immunol. 163, 2592–2600 (1999).
   PubMed Web of Science ®Google Scholar
• Wiedermann U, Jahn-Schmid B, Bohle B et al. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of Type I allergy. J. Allergy Clin. Immunol. 103, 1202–1210 (1999).
   PubMed Web of Science ®Google Scholar
• Hufnagl K, Wagner B, Winkler B et al. induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. Clin. Exp. Immunol. 133, 170–176 (2003).
   PubMed Web of Science ®Google Scholar
• Winkler B, Bolwig C, Seppala U et al. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 110, 376–385 (2003).
   PubMed Web of Science ®Google Scholar
• Jutel M, Jaeger L, Suck R et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116, 608–613 (2005).
   PubMed Web of Science ®Google Scholar
• Valenta R. The future of antigen-specific immunotherapy of allergy. Nature Rev. Immunol. 2, 446–453 (2002).
   PubMed Web of Science ®Google Scholar
• Hoyne GF, O´Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178, 1783–1788 (1993).
   PubMed Web of Science ®Google Scholar
• Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl Acad. Sci. USA 90, 7608–7612 (1993).
   PubMed Web of Science ®Google Scholar
• Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8, 1937–1945 (1996).
   PubMed Web of Science ®Google Scholar
• Müller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101, 747–754 (1998).
   PubMed Web of Science ®Google Scholar
• Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189, 1885–1894 (1999).
   PubMed Web of Science ®Google Scholar
• Alexander C, Ying S, Kay AB, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-γ+ T helper Type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35, 52–58 (2005).
   PubMed Web of Science ®Google Scholar
• Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy 59, 1079–1101 (2004).
   Google Scholar
• Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. J. Allergy Clin. Immunol. 111, 854–861 (2003).
   PubMed Web of Science ®Google Scholar
• Oldfield WLG, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised control trial. Lancet 360, 47–53 (2002).
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Leitner A, Kalchhauser H et al. Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice. FASEB J. 12, 1635–1642 (1998).
   PubMed Web of Science ®Google Scholar
• Focke M, Linhart B, Hartl A et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin. Exp. Allergy 34, 1525–33 (2004).
   PubMed Web of Science ®Google Scholar
• Zeiler T, Taivainen A, Rytkonen M et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J. Allergy Clin. Immunol. 100, 721–727 (1997).
   PubMed Web of Science ®Google Scholar
• Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J. Clin. Invest. 99, 1673–1681 (1997).
   PubMed Web of Science ®Google Scholar
• Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB J. 15, 2045–2047 (2001).
   PubMed Web of Science ®Google Scholar
• Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101, 14677–14682 (2004).
   PubMed Web of Science ®Google Scholar
• Ipsen H, Loewenstein H. Isolation and immunochemical characterization of the major allergen of birch pollen (Betula verrucosa). J. Allergy Clin. Immunol. 72, 150–159 (1983).
   PubMed Web of Science ®Google Scholar
• Breiteneder H, Pettenburger K, Bito A et al. The gene coding for the major birch pollen allergen, Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J. 8, 1935–1938 (1989).
   PubMed Web of Science ®Google Scholar
• Jarolim E, Rumpold H, Endler AT et al. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 44, 385–395 (1989).
   PubMed Web of Science ®Google Scholar
• Niederberger V, Pauli G, Grönlund H et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J. Allergy Clin. Immunol. 102, 579–591 (1998).
   PubMed Web of Science ®Google Scholar
• van Hage-Hamsten M, Kronqvist M, Zetterstrom O et al. Skin test evaluation of genetically engineered hypoallergenic derivates of the major birch pollen allergen, Bet v 1. Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J. Allergy Clin. Immunol. 104, 969–977 (1999).
   PubMed Web of Science ®Google Scholar
• Pauli G, Purohit A, Oster J-P et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with Bet v 1 wild type by skin prick and intradermal testing: results obtained in a French population. Clin. Exp. Allergy 30, 1076–1084 (2000).
   PubMed Web of Science ®Google Scholar
• van Hage-Hamsten M, Johansson E, Roquet A et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild type in patients with allergic rhinitis. Clin. Exp. Allergy. 32, 1448–1453 (2002).
   PubMed Web of Science ®Google Scholar
• Reisinger J, Horak F, Pauli G et al. Allergen-specific IgG antibodies in nasal secretions induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116, 347–354 (2005).
   PubMed Web of Science ®Google Scholar
• Gafvelin G, Thunberg S, Kronqvist M et al. Cytokine and antibody responses in birch pollen allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int. Arch. Allergy Immunol. 138(1), 59–66 (2005).
   PubMed Web of Science ®Google Scholar